Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07495852
Recruiting Phase 3

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852 · tracked via the Priya Life Science USA tracker
Sponsor
Glaukos Corporation
Phase
Phase 3
Started
2026-02-17
Last updated
2026-03-30

Condition(s) studied

Glaucoma

Investigational drug(s) / intervention(s)

Gen 2 Travoprost Intracameral Implant →Timolol eye drops 0.5% →Sham Procedureplacebo eye drops

Gen 2 Travoprost Intracameral Implant: Travoprost

Timolol eye drops 0.5%: Timolol 0.5%

Sham Procedure: Sham implant administration

placebo eye drops: Artificial Tears

Study summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Primary outcome measure(s)

  • Intraocular pressure (IOP) — 3 months
    Change from baseline in diurnal IOP in the study eye at 8am and 10am at each of Day 11, Week 6, and Month 3 visits

Trial sites (1)

FacilityCityRegionStatus
Glaukos Investigative Site Dothan Alabama Recruiting

More Glaukos Corporation trials in the USA

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus Recruiting
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus Recruiting
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Recruiting
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone Recruiting
iDose TR Administration in an Office-Based Surgery Setting Recruiting

Other trials for the same condition

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) Recruiting
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution Active, not recruiting
Comparative Study of the Tomey FT-1000, and Goldmann Applanation Tonometer (GAT) Recruiting
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Recruiting
Visual Field Analysis With Artificial Intelligence Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07495852 on ClinicalTrials.gov ↗ ← All trials in the USA